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ABSTRACT 
 
IN VITRO EVALUATION OF COMB-TYPE POLY(ETHYLENE 
GLYCOL)-CELL INTERACTIONS AND COMPARISON WITH 
LINEAR POLY(ETHYLENE GLYCOL) 
 
The aim of this study is to investigate physicochemical characteristics and in 
vitro cell interactions of comb-type poly(ethylene glycol) (Mn= 10 700 and Mn= 20 200 
g/mol, p(PEG-A) 10K and p(PEG-A) 20K, respectively) in comparison with linear 
poly(ethylene glycol) (Mn= 10 000 and Mn= 20 000 g/mol, PEG 10K and PEG 20K, 
respectively) of equivalent molecular weight. In vitro cytotoxicity, cell uptake and 
intracellular distribution profile of comb-type and linear polymers were investigated 
using human lung adenocarcinoma epithelial cells (A549).  
The dynamic light scattering (DLS) analysis showed that the comb-type 
polymers had smaller hydrodynamic diameters (Dh) (4.5±0.3 nm - 5.9±0.3 nm) than 
linear PEGs (5.6±0.5 nm - 7.8 ±0.2 nm) in water and phosphate buffer solution at pH 
7.4. While the Dh of p(PEG-A) 10K and 20K in RPMI 1640 and RPMI 1640 containing 
10% FBS ranged between 44.4±1.8 nm and 58±5.3 nm, the Dh of PEG 10K and 20K in 
the same media were between 54.5±4.7 nm and 63.5±2 nm. According to the AFM 
analysis, PEG 10K forms supramolecular linear structures whereas p(PEG-A) 10K 
forms spherical structures.  
None of the polymers caused significant cytotoxic effect on A549 cells under the 
conditions tested via a cell viability assay. Cell uptake studies via flow cytometry 
showed that the uptake of p(PEG-A) 10K by A549 cells was significantly higher than 
the other polymers tested. All polymers were internalized by A549 cells via an active 
transport mechanism. The uptake increased with increasing polymer concentrations. 
None of the polymers affected the cell cycle of A549 cells under the conditions tested. 
Both the comb-type and linear PEGs were found to localize in the lysosomes of A549 
cells. 
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ÖZET 
TARAK TİPİ POLİ(ETİLEN GLİKOL)-HÜCRE ETKİLEŞİMLERİNİN 
İN VİTRO DEĞERLENDİRİLMESİ VE LİNEER POLİ(ETİLEN 
GLİKOL) İLE KARŞILAŞTIRILMASI 
 
Bu çalışmanın amacı, eşdeğer moleküler ağırlığa sahip tarak-tipi PEG (MA= 10 
700 ve MA=20 200 g/mol, p(PEG-A) 10K ve p(PEG-A) 20K, sırasıyla) ve lineer 
PEG’in (MA= 10 000 ve MA=20 000 g/mol, PEG 10K ve PEG 20K, sırasıyla) 
fizikokimyasal karakteristliklerinin ve in vitro hücre etkileşimlerinin karşılaştırmalı 
olarak incelenmesidir. Dört farklı polimerin, in vitro sitotoksisite, hücre alımı, hücre-içi 
dağılım profilleri ve hücre döngüsüne etkileri insan akciğer adenokarsinom epitel 
hücrelerinde (A549) incelendi. 
Dinamik ışık saçılımı (DLS) analizleri, tarak-tipi polimerin hidrodinamik 
çaplarının (4.5±0.3 nm - 5.9±0.3 nm) lineer PEG’e göre (5.6±0.5 nm - 7.8 ±0.2 nm) 
suda ve fosfat tampon çözeltisinde daha küçük olduğunu gösterdi. Hücre kültür 
ortamında, RPMI 1640 ve 10% FBS içeren RPMI 1640, p(PEG-A) 10K and 20K’nın 
hidrodinamik çapları 44.4±1.8 nm ve 58±5.3 nm iken, PEG 10K and 20K’nın 54.5±4.7 
nm ve 63.5±2 nm’dir. AFM analizleri, PEG 10K supramoleküler lineer form 
yapısındayken, p(PEG-A) 10K’nın küresel yapıda olduğunu göstermiştir. 
 Polimerler, A549 hücrelerinde önemli derecede sitotoksik etki göstermemiştir. 
Hücre alımı çalışmaları, A549 hücrelerine p(PEG-A) 10K’nın diğer polimerlere göre 
önemli derecede fazla alındığını göstermiştir. Tüm polimerler A549 hücreleri tarafından 
aktif taşıma ile alınmıştır. Hücre alımı, artan polimer konsantrasyonuyla artmıştır. A549 
hücrelerinin hücre döngüsüne, polimerlerin etkisi gözlenmemiştir. Polimerler, A549 
hücrelerinin lizozomlarında lokalize olmuştur. 
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CHAPTER 1  
INTRODUCTION 
Poly(ethylene glycol) (PEG) is a non-toxic, non-immunogenic and uncharged 
polymer that consists of repeating ethylene oxide units along a linear polymer backbone 
(Figure 1.1). PEG has been widely used in pharmaceutical applications due to its low 
toxicity, low protein adsorption property and non-immunogenicity. Biomolecular 
therapeutics display better in vivo properties and performance when covalently 
conjugated with PEG chains (Zalipsky 1995). PEG having varying molecular weights 
and narrow polydispersity* is commercially available and has been widely used for 
preperation of protein conjugates, PEG-liposomes and micelles and PEG-drug 
conjugates for pharmaceutical applications (Zalipsky and Milton Harris 1997). 
 
 
Figure 1.1. The chemical structure of linear PEG 
 
Conjugating biomolecules with PEG, a strategy termed PEGylation, is now an 
important method not only for therapy, but also diagnosis and organic biocatalysis 
(Veronese and Pasut 2005). 
 
 
 
 
 
*Polydispersity index (PDI) is a measure of molecular weight distribution of polymers. The PDI has a 
value equal to or greater than 1.If the polymer chains are uniform in chain length, the PDI is equal to 1 
(Rogošić, Mencer, and Gomzi 1996). 
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PEGylation of therapeutics has several advantages: PEG reduces 
immunogenicity of the therapeutics molecules. The hydrodynamic volume of the 
therapeutic molecules increases after PEGylation, which results in increased in vivo 
circulation half-lifes of therapeutics by reducing renal clearance and restricting body 
distribution. PEGylation also increases stability and solubility of biomolecules and 
protects biomolecules againts degradation by enzymes (Zalipsky and Milton Harris 
1997). 
Despite these favorable properties of PEGylation, there are several 
disadvantages of PEGylation technology: 
1. PEG is a non-degradable polymer. Below 20 kDa molecular weight, it is 
excreted from the body via kidneys. However above 50 kDa molecular weight, it is 
eliminated more slowly and it accumulates at liver that leads to macromolecular 
syndrome (Bouladjine et al. 2009, Veronese and Pasut 2005).  
2. While the higher molecular weight PEG can protect therapeutics better, the 
nondegradable structure of PEG, which leads to accumulation at liver, limits the use of 
high molecular weight polymers in therapeutic applications.  
3. PEG has poor cell uptake because of hydrophilic nature and large 
hydrodynamic volume (Caliceti and Veronese 2003). This is especially important for 
formulations or therapeutics that need to reach intracellular targets, such as anticancer 
drug carrying nanoparticles and DNA/RNA based therapeutics. It has been reported that 
PEGylated conjugates showed little uptake due to the shielding effect of PEG inhibiting 
electrostatic interactions with anionic cell surfaces (Kunath et al. 2003).  
4. Also PEGylation may decrease pharmacological activity of biotherapeutics. 
Interferon-alpha-2a modified with 40 kDa PEG retains only 7% of the initial therapeutic 
activity of the protein (Bailon et al. 2001). 
In recent years new PEG architectures have been developed to improve the 
applications of PEGylation technology. These include branched PEGs such as 3-armed, 
4-armed, star and comb-type PEGs.  
Comb-type PEG polymers that are formed by grafting multiple linear PEG 
oligomers to methacrylate or acrylate polymer backbones, have attracted attention as 
superior alternatives to linear and multi-armed PEGs (Figure 1.2) (Ryan et al. 2009, 
Sayers et al. 2009). Due to their umbrella-like shape, comb-type PEGs can be more 
efficient in enhancing the circulation half-life of biomolecules in body by increasing 
resistance to degradative enzymes. The most important advantage of comb-type PEG 
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over linear and multi-armed PEGs is that it contains short PEG side chains attached to 
the backbone via the degradable ester bonds. Upon degradation of ester bonds, short 
PEG chains and also the remaining backbone are released. These short segments are in 
the bio-eliminable molecular weight range (Magnusson et al. 2010). Due to enzyme 
degradable and hydrolyzable ester linker, comb-type PEG may overcome the limitations 
of linear PEG, linked to its nondegradable structure such as liver accumulation problem. 
Another important feature of comb-type PEG is that it can be synthesized with 
controlled molecular weight, narrow molecular weight distribution and defined-end 
group at mild laboratory conditions via controlled/living radical polymerization 
techniques such as reversible addition fragmentation chain transfer (RAFT) 
polymerization and atom transfer radical polymerization (ATRP) techniques (Ryan et 
al. 2009, Moad, Rizzardo, and Thang 2009, Lowe, Hoyle, and Bowman 2010). In recent 
publications, comb-type PEG has shown to improve in vivo half-life of proteins and 
stability of nucleic acids against nucleases (Gunasekaran et al. 2011).  
The aim of this thesis is to investigate interactions of comb-type PEG, 
poly(polyethylene glycol) methyl ether acrylate (PEG-A) with in vitro cultured cells in 
comparison with linear PEG. To do this, comb-type PEGs having two different 
molecular weights were first synthesized via RAFT polymerization and 
physicochemically characterized using Nuclear Magnetic Resonance (NMR), Gel 
Permeation Chromatography (GPC), Dynamic Light Scattering (DLS) and Atomic 
Force Microscopy (AFM). Commercially available linear PEGs of equivalent molecular 
weigths were also analyzed using the same techniques. Comb-type and linear PEGs 
were then tested in in vitro cytotoxicity, cell uptake, cell cycle and intracellular 
distribution experiments using a human lung adenocarcinoma epithelial cell line 
(A549). The methods and results are presented in Chapters 3 and 4, respectively. 
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Figure 1.2. The chemical structure of branched and comb-type PEG 
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CHAPTER 2  
LITERATURE REVIEW 
2.1. PEGylation Technology 
Advances in molecular biology and biotechnology have led to proteins, peptides, 
RNA and DNA-based biomacromolecular therapeutics that can be used for treatment of 
various diseases. For treatment of today, a large number of biopharmaceuticals are 
commercially available for human use. Despite their enormous potential, 
biopharmaceuticals have some important limitations in vivo such as immunogenicity, 
low solubility and nonspecific biodistribution (Veronese and Pasut 2005). In addition, 
biopharmaceuticals are prone to degradation by enzymes and rapidly excreted from the 
body in minutes (Jevševar, Kunstelj, and Porekar 2010).  
PEGylation which is the covalent attachment of poly(ethylene glycol) (PEG) 
chains to bioactive substances has been used to overcome these limitations. PEGylation 
was first proposed by Davis et al. in 1970 to improve pharmacokinetic properties of 
proteins (Harris, Martin, and Modi 2001, Matsushima et al. 2001). 
The PEGylation Technology has been widely used in pharmaceutical 
applications to improve properties of proteins, enzymes and anticancer drugs. It has also 
been used to prepare, stealth micelles and liposomes as efficient drug delivery vehicles. 
In addition, PEG hydrogels have been used for wound covering and cell encapsulation 
(Zalipsky and Milton Harris 1997). 
PEGylation improves pharmacokinetic properties of biotherapeutics and drug 
delivery systems via various ways: PEG increases hydrodynamic volume of 
biomolecules/systems it is attached to (Figure 2.1) (Veronese and Pasut 2005, Harris, 
Martin, and Modi 2001). This reduces the rapid clearance by kidneys. PEGylation 
enhances the biological half-life of biomolecules/drug delivery systems by providing 
enhanced resistance against enzymes, reduced immunogenecity and recognition by 
reticuloendothelial system by shielding their surfaces (Gunasekaran et al. 2011). 
Acording to Figure 2.1 PEG shields the protein surface from degrading enzymes and 
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antibodies by steric hindrance. Moreover, the size of the conjugate increases so that the 
kidney clearance of the PEGylated protein decreases (Veronese and Pasut 2005).         
PEGylation may also alter the biodistribution of biomolecules/drug delivery 
systems. Briefly, it increases the overall yield of the therapy. 
 
         
Figure 2.1. A protein-PEG conjugate 
 
Along with these important advantages, PEGylation has several limitations: 
Biotherapeutics’ pharmacological activity often decreases after PEGylation. Even 
though decreasing the pharmacological activity of biotherapeutics, PEGylation is the 
preferable method to increase the blood circulation half-life of biotherapeutics. Several 
protein therapeutics are taken up in the liver. By masking both recognition sites and 
charges, PEGylation reduces the protein uptake by liver cells (Kompella and Lee 2001). 
The liver clearance of PEG is size-dependent indicating a minimum around a molecular 
weight of 50 kDa. The higher-molecular-weight PEGs accumulate in the Kupffer cells 
of liver tissue (Caliceti and Veronese 2003, YAMAOKA, TABATA, and IKADA 1995, 
1994). It is not easy to estimate the kidney excretion limit of PEG by looking only at the 
kidney clearance threshold of proteins (~60 kDa, albumin). Because, the high water 
affinity of PEG increases the polymer’s hydrodynamic volume up to 3–5 times that of a 
globular protein with an equivalent molecular weight. Therefore, kidney clearance 
threshold for PEG is 3-5 times smaller when compared with globular proteins. The 
linear and flexible nature of the chains help PEG to cross the glomerular membranes by 
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a ‘snake-like’ movements (Veronese and Pasut 2005, Jevševar, Kunstelj, and Porekar 
2010). 
Another important limitation of PEGylation has been reported to be the poor 
cellular uptake of linear PEG.  Kunath et al. prepeared RGD peptide-polyethylenimine 
(PEI)- PEG copolymers and reported that PEG can reduce the positive charge of PEI 
and also the cellular uptake of the copolymer. The poor uptake was attributed to the 
shielding effect of PEG inhibiting electrostatic interactions with anionic cell surface 
preventing nonspecific uptake. It is also possible that PEG blocks statistically exist as a 
cloud conformation due to the high flexibility of PEG chains. This conformation may 
prevent interactions between targeting RGD residues of the copolymers and integrin 
receptors on the cell surface. Therefore RGD peptide with PEG spacer did not lead to an 
effective targeting (Kunath et al. 2003, Torchilin et al. 1994). In gene therapy, 
PEGylation of adenovirus vectors (Ads) is an efficient strategy. Although high 
transduction efficiency, which is characteristic property of Ads, decreased owing to the 
steric hindrance of CAR by PEG chains. While PEG-Ads decreased gene expression in 
CAR-positive cells, RGD-PEG-Ad enhanced gene expression about 200-fold higher 
than PEG-Ads (Eto et al. 2005). 
During PEG conjugation, the biological activity loss of therapeutics have been 
prevented by exploiting a different architecture of linear PEG used for modification. It 
was indicated that the activity loss of enzymes (such as asparaginase or uricase) was 
greatly circumvented by using branched PEG instead of linear PEG due to the hindrance 
by the bulky structure of the polymer approaching to the active site cleft (Figure 2.2). 
The high steric hindrance of branched PEG may be advocated to explain the lower 
inactivation of enzymes as compared to linear PEG of the same size (Veronese 2001). 
 
 Figure 2.2. Branched PEG has the advantage of a lower inactivation of the enzymes 
during conjugation 
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2.2. Types of PEG Conjugates 
To date, a number of PEGylated proteins have been approved for human use. 
Examples of the approved PEGylated protein therapeutics are listed in Table 2.1. Both 
linear and branched PEG architectures have been used to prepare these commercially 
available PEGylated therapeutics.    
 
Table 2.1. Examples of FDA-approved PEGylated drugs in the market 
 
Conjugate/Company 
 
 
Type of 
  PEGylation 
 
Disease /Treatment 
 
Year of 
Approval 
 
Ref. 
PEG-adenosine 
Deaminase (Adagen®) 
Linear 
PEG 
Severe combined 
immunodeficiency 
disease (SCID ) 
 
1990 (Graham 
2003) 
PEG-asparaginase 
(Oncaspar®) 
Linear 
PEG 
 
Leukemia 1994 (Levy et al. 
1988) 
PEG-interferon-α2b 
(PegIntron®) 
Branched PEG 
12kDa 
 
Hepatitis C 2000 (Grace et al. 
2001) 
 
 
PEG-interferon-α2a 
(Pegasys®) 
Branched PEG 
40kDa 
 
Hepatitis C 2002 (Bailon et al. 
2001) 
PEG-human growth 
hormone mutein 
antagonist (Somavert®) 
 
Linear PEG 5kDa Acromegaly 2002 (Trainer et al. 
2000) 
PEG-anti-VEGF 
aptamer (Pegaptanib, 
Macugen™) 
Branched PEG 
40kDa 
Wet age 
associated macular 
degeneration 
2004 (Ng et al. 
2006) 
 
Different PEG architectures that have been reported in the literature to date is 
shown by Figure 2.3. Among these architectures, linear PEG derivatives having 
molecular weights between 5kDa and 20 kDa have been often used as PEGylation 
reagents (Veronese 2001). For example, Gilbert and Park-Cho (Gilbert and Park-Cho 
(cont. on next page) 
9 
 
2000) used linear monomethoxyPEG (12 kDa) to develop PEG-interferon a-2b (IFN-a-
2b). These conjugates improved pharmacokinetic properties of IFN-a-2b in both 
humans and animals. The second type of PEG architectures that has been widely used in 
PEGylation is the multi-arm PEGs. Two or more linear PEG chains are covalently 
linked through a core to prepare multi-arm PEGs. Among multi-arm PEGs, two-arm 
PEGs have been used in clinically approved PEGylated protein therapeutics. Bailon et 
al. (Bailon et al. 2001) conjugated IFN-a-2a with an N-hydroxysuccinimide (NHS) ester 
derivative of two-arm PEG (total molecular weigth 40 kDa, each linear PEG chain 20 
kDa). These conjugates also showed improved pharmacokinetic properties in animals 
and healthy humans.  
 
              
   Figure 2.3. Types of PEGs backbones and architectures 
 
Conjugation of multi-arm PEGs to proteins increases pH and thermal stability of 
proteins and provides greater stability toward proteolytic digestion. When compared to 
linear PEG, multi-arm PEGs with single reactive functional group have been proven 
more useful in polypeptide and protein. Lysine is the amino acid spacer between two 
PEG molecules in two-arm PEG that offers the advantages of higher protection of 
protein surface as compared to the linear form. Generally, it provides lower 
immunogenicity, higher retention in blood and decreased enzyme inactivation during 
the conjugation (Caliceti, Schiavon, and Veronese 1999). It is indicated that PEG and 
PEG2 (two-arm) derivatives show very different accumulation profiles in the examined 
organs. According to the literature data, the linear PEG derivative does not show 
specific localization in peripheral districts also low amounts of linear PEG’ conjugates 
are found in all the tissues. On the other hand, the PEG2 adduct accumulates at 
significant extent in liver and spleen that rich of reticulo-endothelial cells. Therefore, 
branched shape of this polymer can affect the cell/ conjugate interaction process and the 
10 
 
higher accumulation of the PEG2 derivative can more efficiently stimulate the cell 
phagocytic process with respect to the linear one (Bailon et al. 2001, Caliceti, Schiavon, 
and Veronese 1999, Bendele et al. 1998).  
Multi-arm PEGs have been more efficient in improving the biological half-life 
of protein therapeutics by providing higher steric hindrance effect because of its 
umbrella-like shape, thus leading to more efficiently reduction in immunogenicity and 
better resistance against proteolysis (Ryan et al. 2008, Roberts, Bentley, and Harris 
2012, Ryan et al. 2009). Figure 2.4 shows the difference in the steric hindrance effect of 
linear and two-arm PEGs. The umbrella-like structure of branched PEG defines the 
higher capacity in rejecting approaching cells or molecules as compared to linear PEG 
of the same size (Veronese 2001). 
 
 
Figure 2.4. Linear and Branched PEG-conjugated protein 
 
Comb-type PEG is a new entry to PEG architecture inventory. Comb-type PEGs 
that are composed of multiple PEG chains grafted to methacrylate or acrylate polymer 
backbone have demonstrated to be potent alternatives to linear and multi-arm PEGs for 
enhancing the pharmacokinetics of protein drugs (Sayers et al. 2009). These promising 
PEG architectures have recently been used in conjugation with biomolecules reported 
only by a few publications. The comb-type structure provides an umbrella-shaped 
conjugate and this architecture can increase resistance to proteolytic and nuclease 
attacks and reduce immunogenicity because of enhanced steric effect. It has been shown 
that comb-type PEG, when compared with linear PEG of equivalent molecular weight, 
exhibits greater steric hindrance, hence enhances biostability and lowers clearance rates 
11 
 
of the conjugated biotherapeutics (Gunasekaran et al. 2011, Ryan et al. 2009, Ryan et al. 
2011). Figure 2.5 and Figure 2.6 shows linear PEG and comb-type PEG protein 
conjugates. Moreover, comb-type PEG polymers can be easily synthesized by reversible 
addition fragmentation chain transfer (RAFT) polymerization (Moad, Rizzardo, and 
Thang 2009) and atom transfer radical polymerization (ATRP) techniques (De et al. 
2008) that are relatively new techniques enabling synthesis of polymers with varying 
architectures, such as block and star copolymers, controlled molecular weights and 
narrow polydispersities, and also defined end-group functionalities. End-group 
functionality of polymers allow to crucial synthetic strategies to be applied for site-
specific PEGylation (Gunasekaran et al. 2011). Because of these properties, PEGylation 
using comb-type polymers may play an important role in enhancing the potential of 
both gene and protein therapeutics (Asayama et al. 1998, Srividhya et al. 2006). 
 
 
Figure 2.5. Linear-PEG conjugated protein 
 
           
 Figure 2.6. The comb-type PEG conjugated protein 
 
 
 
 
 
 
protein
protein
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2.2.1. Comb-type PEGylated Biomolecules as Potential Therapeutics 
 
Heredia et al. (Heredia et al. 2008) synthesized a poly(polyethylene glycol 
methyl ether acrylate) p(PEG-A) (comb-type PEG-A) with a pyridyl disulfide end 
functionality via reversible addition fragmentation chain-transfer (RAFT) 
polymerization, to conjugate with a-thiol-modified of siRNA. The authors showed a 
88% conjugation yield. Following the same conjugation method (Figure 2.7) 
Gunasekaran et al. (Gunasekaran et al. 2011) prepared siRNA comb-type PEG-A 
conjugates using pyridyl disulfide-functional poly(polyethylene glycol methyl ether 
acrylate) p(PEGA)s with two different molecular weights (low molecular weight 
(LMWC) and high molecular weight (HMWC)). The conjugates were shown to be 
cleavable as they contained reversible disulphide linkages. Moreover, when compared 
to thiol-modified and unmodified siRNA, siRNA-p(PEG-A) conjugates sharply 
increased nuclease resistance and serum stability. The unmodified siRNA and thiol-
modified siRNA were completely degraded within 10 and 48 h in 80% active fetal 
bovine serum (FBS), respectively. However, LMWC and HMWC degraded much 
slower; the HMWC degradation was only 16% at 72 h. A previous study (Kim et al. 
2006) indicated that in 50% fetal bovine serum, the siRNA-linear PEG (Mn= 5 000) 
conjugates had higher stability than non-modified siRNA. The unmodified siRNA 
showed almost complete degradation after 8 h incubation in the serum-containing 
medium. In contrast, the siRNA–PEG conjugate could last up to 16 h without a 
significant loss of integrity in the same condition. PEG-based polymers with high stable 
siRNA conjugates can be contributed to the steric hindrance effect of the polymer by 
preventing the interactions between the nucleases and siRNA. Even though not directly 
comparable, umbrella-like shape of p(PEGA) attribute to provide greater protection of 
siRNA. The higher serum stability of siRNA-p(PEG-A) conjugates relative to siRNA-
linear PEG conjugates can be attributed to the umbrella-like shape of p(PEG-A), 
potentially providing greater protection to siRNA. 
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Figure 2.7. Conjugation of thiol-modified siRNA with RAFT-synthesized 
pyridyldisulfide functionalized p(PEGA) (Gunasekaran et al. 2011) 
 
Gao et al. (Gao et al. 2009) reported comb-type poly(oligo(ethylene glycol) 
methyl ether methacrylate) [p(OEGMA)] (Number average moleculer weight: 120 
kDA, PDI: 1.4) conjugate with myoglobin protein. After administration of these 
conjugates to mice, distribution phase of the myoglobin-p(OEGMA) conjugate 
[hydrodynamic radius (Rh): 13 nm] showed a 41-fold increase in blood exposure, also 
final elimination phase was prolonged until 18 hours compared to unmodified 
myoglobin (Rh:1.7 nm). This exciting results indicated that comb-type PEG stably and 
dramatically prolongs the half-life of a protein after intravenous administration in vivo. 
Similarly, Gao et al. (Gao et al. 2010) reported the conjugates of 
poly(oligoethylene glycol) methyl ether methacrylate p(OEGMA) with Green 
Fluorescent Protein (GFP). The authors showed that the blood exposure of the conjugate 
(hydrodynamic radius (Rh): 21 nm) was increased 15-fold when compared to 
unmodified protein (Rh: 3.0 nm) after intravenous administration to mice. Besides, 
compared to the unmodified protein, the conjugate showed a 50-fold increase in tumor 
accumulation, 24 h after intravenous administration to tumor-bearing mice. These 
results showed that comb-type PEG conjugation improves significantly in vivo 
pharmacological profile of a protein. 
Ryan et al. (Ryan et al. 2009) conjugated Salmon calcitonin (sCT) via its N-
terminal cysteine to a comb-typePEG, sCT-PolyPEG6,5K (Number average molecular 
weight: 6.5 kDA) and linear PEG, sCT-PolyPEG5K (Number average molecular weight: 
5 kDa) to investigate benefits of site-specific attachment to a comb-shaped polymer. 
Intracellular cyclic adenosine monophosphate (cAMP) was used for measuring the 
bioactivity of conjugates in human breast cancer (T47D) cells in vitro. Both analysis by 
RP-HPLC and cAMP activities showed that after 30 min of incubation in rat liver 
homogenate, sCT was totally degraded and sCT-PEG5K retains only 7% of its 
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bioactivity after 30 min. In comparison, sCT-PolyPEG®6.5K showed a much slower rate 
of liver metabolism and more resistance to liver enzymes. According to biological 
activities of sCT-PolyPEG®6.5K and sCT-PEG5K conjugates in vitro, compared with 
non-modified sCT, sCT-PolyPEG6,5K and sCT-PolyPEG5K maintained 85% and 92% of 
the bioactivity.  Using lactate dehydrogenase (LDH) assay, cytotoxicity of conjugates 
was assessed and this assay indicated that both polymers were non-toxic. While both 
sCT-PolyPEG®6.5K and sCT-PEG5K were resistant to metabolism by serine proteases, 
homogenates and serum, PolyPEG®6.5K showed higher resistance than other. Besides, 
non-modified form of the protein was degraded and sCT-PEG5K showed far less 
bioactivity when compared to PolyPEG®6.5K. While both conjugates reduced serum 
calcium levels, PolyPEG®6.5K increased the T1/2 and AUC of serum sCT with respect to 
sCT-PEG5K and sCT. In order to assess concentration and hypocalcaemic response of 
sCT in the blood plasma following i.v. administration to rats, pharmacokinetics and in 
vivo biological efficacy of sCT-PEG5K and sCT-PolyPEG®6.5K were evaulated. Both 
types of conjugates and sCT had similar hypocalcaemic effects and they reached a 
maximum at 240 min, but sCT-PolyPEG®6.5K reached a maximum at 120 min 
compared sCT and sCT-PEG5K. Therefore, PolyPEG® improved pharmacokinetic 
profiles of sCT. 
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CHAPTER 3  
MATERIALS AND METHODS 
3.1. Materials 
Poly(ethylene glycol) methyl ether acrylate (PEG-A) (number-average 
molecular weight Mn = 480 g/mol)  was purchased from Aldrich.  Poly(polyethylene 
glycol) methyl ether acrylate p(PEG-A) (Mn= 10 700 g/mol, PDI= 1,21 p(PEG-A) 10K 
and Mn= 20 200g/mol, PDI=1,26 p(PEG-A) 20K) was synthesized according to the 
procedure reported elsewehere (Heredia et al. 2008).  A brief description of the polymer 
synthesis is given in the section below. Thiol PEG, mPEG-SH (Mn= 10 000 g/mol, 
PDI=<1.08 PEG 10K) was purchased from Nanocs. O-[2-(3-
Mercaptopropionylamino)ethyl]-O′-methylpolyethylene glycol 20′000 (Mn= 20 000 
g/mol, PDI=<1.08 PEG 20K ) was bought from Fluka. 3-
(Benzylsulfanylthiocarbonylsulfanyl)-propionic acid (BSPA) that was synthesized by 
Assoc. Prof. Dr. V. Bulmuş at University of New South Wales, Sydney according to a 
procedure reported elsewhere (Boyer, Bulmus, and Davis 2009) was used as received. 
The initiator, 2,2′- Azoisobutyronitrile (AIBN) was crystallized twice from methanol 
prior to use.   
All other chemicals were used as received. Diethyl ether, acetonitrile, N,N-
dimethylformamide, triethylamine (TEA), hexylamine (HEA), tris(2-
carboxyethyl)phosphine hydrochloride (TCEP), deuterated water (D2O),  deuterated 
chloroform (CDCl3), N’N-dimethylacetamide (DMAc, HPCL grade  ≥ %99.9) were 
purchased from Sigma. Oregon Green® 488 Maleimide and Propidium Iodide were 
bought from Invitrogen. Dialysis membrane (MWCO= 3 500) was purchased from 
Spectrum® Laboratories. 
RPMI-1640 (Roswell Park Memorial Institute 1640 Medium) medium (L-
Glutamine, HEPES 25mM) and FBS (Foetal Bovine Serum) were obtained from Gibco. 
PBS (phosphate buffer saline solution, pH 7.1, 0.1 mM) was prepared using relevant 
mono and dibasic salts and NaCl. Thiazolyl Blue Tetrazolium  Blue (MTT) reagent was 
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bought from Sigma- Aldrich.  LysoTracker® Red DND-99 and DAPI dilactate (organel 
dyes) were purchased from Invitrogen. 
Human lung adenocarcinoma epithelial (A549) cells were kindly donated by 
Assoc. Prof. Dr. Y. Baran and Biotechnology and Bioengineering Research and 
Application Center, İzmir Institute of Technology, İzmir, Turkey. 
 
3.2. Methods  
3.2.1. Synthesis of Poly(ethylene glycol) Methyl Ether Acrylate   
p(PEG-A) 
 
Poly(polyethylene glycol methyl ether acrylate) p(PEG-A) was synthesized 
according to the literature (Heredia et al. 2008). The polymerization reaction is shown 
in Figure 3.1. Briefly, BSPA, PEG-A and AIBN were dissolved in acetonitrile. The 
solution was purged with nitrogen for 15 min at 0
◦
C and then immersed in an oil-bath at 
65
◦
C. At the end of polymerization time, the solution was partially evaporated under 
vacuum. The polymer was then precipitated in cold diethyl ether to remove any traces 
of monomers and unreacted RAFT agent. The precipitation process was then repeated 
ten times. The precipitated polymer was collected and dried under vacuum. 
For the synthesis of p(PEG-A) having Mn and PDI of 10 700 g/mol and 1.21, 
respectively, BSPA (6 mg, 0.0261 mmol), PEG-A (0.72 g, 0.0015 mol) and AIBN (0.75 
mg, 0.0051 mmol) were mixed in 1.5 ml of acetonitrile to yield a mole ratio of 
[BSPA]0/[PEG-A]0/[AIBN]0= 1/30/0.2. The polymerization time was 4 h. For the 
synthesis of p(PEG-A) having Mn and PDI of 20 200g/mol and 1.26, respectively, 
BSPA (6 mg, 0.0261 mmol), PEG-A (0.72 g, 0.0015 mol) and AIBN (0.75 mg, 0.0051 
mmol) were mixed in 1.5 ml acetonitrile to yield a mol ratio of [BSPA]0/[PEG-
A]0/[AIBN]0 = 1/60/0.2. The polymerization time was 6 h.  
  The polymers were characterized by gel permeation chromatography (GPC) 
using DMAc as mobile phase and 
1
H-NMR spectroscopy using D2O as a solvent. 
Monomer conversions were determined by 
1
H-NMR spectroscopy of the polymerization 
mixture (before purification of the polymer) by comparing the area of the vinylic 
protons ( δ ~ 5.4-6.3 ppm, (3H)) to the area of the PEG characteristic protons (δ ~ 4,3 
ppm, (2H)). 
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The number average molecular weight (Mn) was estimated by 
1
H-NMR of the 
purified polymer using 3.1: 
 
Mn=  [(I
CH
 at 4.0 ppm / (I
phenyl)/5) × MWPEG-A] + MWRAFT, with I
CH
 at 4.0 ppm, I
phenyl
,  
MWPEG-A and MWRAFT (3.1) correspond to the intensity of signal at 4.0 ppm and 
intensity of signal at 7.2-7.4 ppm, molecular weight of PEG-A monomer and molecular 
weight of RAFT agent, respectively. 
 
 
Figure 3.1. Synthesis of polyethylene glycol ethyl methyl ether acrylate p(PEG-A)  
(Mn=10 700 and 20 200g/mol ) 
 
3.2.2. End-group Modification of p(PEG-A) via Aminolysis 
 
The RAFT end-group of the polymers was aminolyzed to yield thiol-ended 
polymers as shown in Figure 3.2. Briefly, for each polymer, p(PEG-A) (0,006 M), HEA 
(0,06 M) and TEA (0,06 M) were dissolved in acetonitrile. The solutions were purged 
for 15 min with nitrogen to remove oxygen and then left to be shaken at room 
temperature for 24 h. After reaction time, acetonitrile was removed by vacuum 
evaporation. The polymers were then precipitated in cold diethyl ether (10 times) and 
dried under vacuum. The product was then characterized by 
1
H-NMR spectroscopy 
using D2O as a solvent. Also RAFT end-group modification conditions for PEG-A (Mn= 
10 700 and 20 200g/mol) was as follows: [PEG-A]0/[HEA]0/[TEA]0 = 1/10/10. The 
reaction conditions for both polymers (Mn= 10 700 and 20 200g/mol) are detailed in 
Table 3.1. 
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Table 3.1. The aminolysis conditions. 
Polymers Polymer (g) 
(mole) 
HEA (g) 
(mole) 
TEA (g) 
       (mole) 
 
Solvent  
Amount (ml) 
 
p(PEG-A)  
Mn=10 700 
 
0.15, 
1.4× 10-5 
 
0.14, 
1.4 ×10-4  
 
0.14, 
1.4 ×10-4  
 
 
       
         2,1  
p(PEG-A)  
Mn=20 200 
0.15, 
0,74× 10-5 
7,3, 
0,74 ×10-4  
7,3, 
0,74 ×10-4 
       
         1,1  
     
 
 
Figure 3.2. Chemical modification of PEG-A (Mn= 10 700; 20 200g/mol) end-group by 
aminolysis 
 
3.2.2.1. Preparation of Ethylene Glycol Ended-Polymers for  
Cytotoxicity Experiments 
 
Since both the RAFT synthesized comb-type polymers and purchased linear 
polymers possessed a reactive thiol end-group, the monomeric unit (ethylene glycol) 
was used to cap the thiol-end groups before cytotoxicity experiments. The reaction is 
shown in Figure 3.3. The thiol-terminated polymers were reacted with poly(ethylene 
glycol) methly ether acrylate monomer (PEG-A) in the presence of tris(2-
carboxyethyl)phosphine hydrochloride (TCEP).  For each polymer (0.11 g, 0,01 M), 
TCEP (0,2 M) and monomer (0.2 M) were dissolved in phosphate buffer solution at pH 
19 
 
7.1. The solution was purged with nitrogen for 30 min and left to be stirred. After 20 h, 
fresh TCEP (0,2 M) was added to the reaction medium under nitrogen. After another 4 
h, the polymer was purified by dialysis against water using a membrane with a MW cut 
off 3500 Da for 4 days and finally freeze-dried. The final product was characterized by 
1
H NMR spectroscopy using D2O as a solvent.  
 
 
 
         Figure 3.3. Preparation of ethylene glycol ended comb-type polymers 
 
3.2.2.2.  Preparation of Fluorescent Labelled Polymers for Cell Uptake 
and Intracellular Distribution Experiments 
 
p(PEG-A)s and PEGs were labeled with Oregon Green maleimide 488. Firstly 
Oregon Green maleimide 488 (5 mg, 1.08×10-5 mol) was dissolved in 108 μl DMF to 
have a stock dye solution of 100 mM. The dye solution (24.5μl, 0,25 ×10-5 mol) was 
added to polymer solution in phosphate buffer solution (0.1M, 500 μl, 0.05×10-5 mol). 
TCEP (0.02 M, 2.8 mg, 1 ×10-5 mol) dissolved in phosphate buffer solution at pH 7.1 
was also added to the reaction mixture. The reaction solution was purged with nitrogen 
for 10 min and gently shaken overnight at 37
◦
C. The product was then dialyzed against 
water using a membrane with a MW cut off of 3500 Da for 4 days and finally freze-
dried. The labelling of polymers was verified using fluorescence spectrometer (Varian 
Cary Eclipse Fluorescence Spectrometer) and the degree of labelling was determined 
via UV-vis spectroscopy (Perkin Elmer Lambda 25 UV/Vis Spectrometer). 
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3.2.3. Physicochemical Characterization of Polymers  
 
3.2.3.1. NMR and GPC Analyses 
 
1
H Nuclear Magnetic Resonance (NMR) spectroscopy was used to determine 
monomer conversions, molecular weigth of polymers and end-group modifications.   
All 
1
H-NMR spectra were taken using Varian VNMRJ 400 spectrometer at Izmir 
Institute of Technology or Varian Mercury Plus 400 Actively Shielded NMR System at 
EBILTEM NMR Laboratory, Ege University, Izmir. 
Gel permeation chromotography (GPC) was used to determine the molecular 
weight and molecular weight distribution of the polymers. N,N-Dimethylacetamide 
(DMAc) containing 0,05 % w/v LiBr was used as a mobile phase in GPC analyses. GPC 
analyses were performed using a Shimadzu modular system comprising an SIL-10AD 
auto injector, PSS Gram 30 A
◦
 and 100 A
◦ (10 μM, 8x300 mm) guard column and an 
RID-10A refractive-index detector. Calibration was performed with poly(methyl 
methacrylate) standards with low polydispersity with molecular weight ranging from 
410 to 67 000 g/mol. 
 
3.2.3.2. DLS Analysis 
 
Dynamic light scattering (DLS) was used to measure the hydrodynamic radius 
(Rh) of linear PEG and comb-type p(PEG-A) in 5 different media: water, phosphate 
buffer saline (PBS) at pH 7.4, PBS containing 10% fetal bovine serum (FBS), cell 
culture medium RPMI-1640, and RPMI-1640 containing 10% FBS. 0.05 mM polymer 
solutions were prepared in 5 different media and DLS analyses were performed for each 
polymer solution. For measurements, the polymer solutions, (40 μL) was taken into 
ZEN0040 Microcuvettes and placed into a Zetasizer Nano ZS (Malvern, UK) 
(measurement range 0.3nm – 10.0 microns; light source He-Ne laser 633nm Max 5mW; 
Power 100 VA). The measurements were repeated 9 times. Measurement duration was 
adjusted automatically. The refractive index of PEG and p(PEG-A) was 1.46 and 1.48, 
respectively. The properties of dispersant that were used for measurements are listed in 
Table 3.2. 
 
21 
 
Table 3.2. The properties of dispersants used for DLS measurements 
  
Water 
 
PBS 
PBS containing 
10% fetal bovine 
serum (FBS), 
 
RPMI-1640 
RPMI-1640 
containing 
10% FBS 
Refractive 
index  
1.33 (Schiebener et 
al. 1990) 
1.33 1.33 1.33 (Yunus and 
Rahman 1988) 
1.33 
 
Viscosity
(Bihari 
et al. 2008)
 
0.88 0.88 0.88 0.1 0.1 
      
 
3.2.3.3. AFM Analysis 
 
Atomic Force Microscope (AFM) images of polymers were taken using an AFM 
(Solver Pro 7 from NT-MDT, NanoMagnetics Instruments, Ankara) in the tapping 
mode that gave topographical and phase contrast images. 0.05 mM polymer 
concentrations in distilled water was placed on silicon substrate, and the samples were 
dried under atmospheric conditions at room temperature. 
 
3.2.4. Cell Culture Experiments 
 
A549 cells (Human lung adenocarcinoma epithelial cell line) were grown in 
RPMI 1640 medium (RPMI) supplemented with 10% fetal bovine serum (FBS), 1% 
Penicillin–Streptomycin as antibiotic in flasks. The cells were maintained between 80-
90% confluency in a dark cell incubator having 5% carbondioxide (CO2) and 95% 
humidity at 37ºC (Masters 2000). 
 
3.2.4.1. MTT Cell Viability Assay 
 
The effect of linear PEG and comb-type p(PEG-A)s on the viability of cells was 
determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 
Cell Viability assay (Berg, Hansen, and Nielsen 2009). The assay measures the ability 
of living cells to reduce a tetrazolium dye, MTT, to its insoluble formazan giving a 
purple color.    
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Briefly, A549 cells were seeded a day prior to sample exposure at 5000 
cells/well (96 well plate) in culture medium containing 10% FBS/RPMI. Polymer 
sample stocks were prepared in PBS solution, followed by dilution in culture medium. 
The final concentration of PBS exposed to the cells was no more than 0.5% (v/v) for the 
duration of the experiment. Varying concentrations (25, 50, 100 and 200 μM) of 
polymers were added to the cells (0.5–4.6 mg/ml) and then incubated at 37 °C/5% CO2 
for 24 and 72h. Following the 24 and 72 h incubation, the viability of the cell was 
determined by MTT Cell Viability assay. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) dye was added to wells according to manufacturer’ 
protocol. The plates were incubated at 37 °C for 3-4 h and metabolic activity was 
detected by spectrophotometric analysis. The fluorescence was then recorded at 
544Ex/590Em nm (Varioskan Flash, Thermo Electron Corparation, Finland). The cell 
viability (%) was calculated relative to the positive control (cells not treated with 
polymers) according to 3.2. The statistical significance of the results was detected using 
Analysis of variance (ANOVA) Minitab 15 (Minitab Inc., State College, PA, USA). 
 
 
                                                                                                         
Where, 
V sample = viable cell absorbance value in the sample well 
V positive = viable cell absorbance value in the positive control (non treated well) 
 
 
 
 
 
   (3.2) 
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3.2.4.2. Flow Cytometry Analyses 
 
3.2.4.2.1. Cell Uptake  
Uptake of linear PEG and comb-type p(PEG-A) by A549 cells was investigated 
using flow cytometry (BD FACSCantoTM A Flow Cytometer, BD Biosciences, San Jose, 
USA). Firstly, all Oregon Green labelled polymers (linear PEG and comb-type p(PEG-
A)) were prepeared for stock solution in PBS (0,002M) including 50 μM polymer 
concentrations. A549 cells (1ml, 6x10
4
 per well) were seeded in 12 well plates and 
incubated in a humidified atmosphere (37ºC and 4 ºC, 5% CO2) for 24 hours. For 12,5 
μM and 25 μM polymer concentrations, stock solution was diluted. After 24 hours; 
Oregon Green labelled polymers were added wells (20 μl) including 12,5 μM polymer 
concentration.  Thus final concentration of wells were 0.04 mM. The cells and polymers 
were incubated for 1, 3, 6 h at either 4 or 37 °C. Each treatment was performed in 
triplicate. For 25 μM and 50 μM polymer concentrations, respective volumes (20 μl) 
from polymer stock solutions (0,002M) were added to the wells. The cells and polymers 
were incubated for 1 hour at either 37 °C. At the end of incubation, medium was 
collected and the wells were washed with cold PBS. The cells were harvested by 
trypsinization and after washing, collected cells were centrifuged for 5 minutes. 
Supernatant was removed and pellet was re-suspended with 200 μl cold PBS. Data from 
10,000 events were collected per sample and analysed by using FacsDiva V.5.0.3 
software. To detect Oregon green solid state 488 laser used for excitation and 530/30 
filter configuration for Oregon green maleimide were used for detection. 
 
3.2.4.2.2. Cell Cycle 
  
The effect of linear PEG and comb-type p(PEG-A) on the cycle of A549 cells 
was also investigated using flow cytometry. Firstly, all polymers were prepeared for 
stock solution in PBS (1 mM). A549 cells (1ml, 5x10
5
 per well) were seeded in 6 well 
plates and incubated in a humidified atmosphere (37ºC, 5% CO2)  for 24 and 72 hours. 
200 μl of each polymer from stock solution was added to wells to yield a final well 
concentration were 0,16 mM. Each treatment was performed in triplicate. Cells without 
any treatment were considered as negative control. Cells and polymers were incubated 
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for 24 and 72 hours. In addition to this, A549 cells (1ml, 5x10
5
 per well) were seeded in 
6 well plates and incubated in a humidified atmosphere (37ºC, 5% CO2) and 4 ºC to 
detect of only cells cell cycle at this temperature. After the incubation time, medium 
was removed and the wells were washed with cold PBS twice. The cells were harvested 
by trypsinization and washing with cold PBS twice. Collected cells were centrifuged 
and supernatant was removed. The pellet was dissolved with PBS (5 ml) and 
centrifuged. The supernatant was removed and the cells were fixed in cold ethanol (4 
ml) in order to fixation of cells. After fixation, cells were centrifuged at 4
◦
C for 10 
minutes at 1200 rpm. Supernatant was removed and pellet was dissolved in PBS (4 ml). 
The cells were centrifuged again at 4
◦
C for 10 minutes at 1200 rpm and pellet was 
dissolved in 0.1 % Triton X-100 (1 ml) including PBS solution. The cells were then 
treated with RNase A (100 μl, 200 μg/ml) and incubated for 30 minutes at 37 ◦C. At the 
end of incubation, Diploid nuclei were then stained with Propidium iodide (100 μl, 1 
mg/ml) and incubated for 15 minutes at room temperature. Analysis was then performed 
using a FACSCanto A (BD Biosciences, San Jose, USA). To detect Propidium iodide, 
green solid state 488 laser was used for excitation, 556/LP and 585/40 filter 
configurations for PI were used for detection. The data on cellular DNA content and cell 
cycle were analyzed by ModFit LT V.3.0 software (Yılmazel Çakmak 2011). 
 
3.2.4.2.3. Intracellular Distribution  
DAPI is a widely-used nuclear counterstain that stains nuclei specifically. For 
A549 cell lines, DAPI has been shown to stain efficiently the nuclei of A549 cells 
(Bhawe et al. 2004). Firstly, stock solutions of Oregon Green labelled polymers (linear 
PEG and comb-type p(PEG-A)) were prepeared in PBS (0,002 M). A549 cells (1ml, 
5x10
5
 per well) were grown on coverslips inside 6 well plates with culture medium 
containing 10% FBS/RPMI and incubated in a humidified atmosphere (37ºC, 5% CO2)  
for 24 hours. After incubation, Oregon Green labelled polymers were added to wells (20 
μl). Thus final concentration of polymers in wells were 0.04 mM. The cells and 
polymers were incubated for 1 hour at 37 °C. After incubation period, the medium 
containing polymers was removed by washing with PBS three times. Subsequently, 
cells were fixed using fresh 2% paraformaldehyde for 20 minutes. After washing three 
times with PBS, cells were permeabilized with 0.1 % Triton X-100 (1 ml) including 
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PBS solution. Next, cells were blocked with 3% BSA in 0.1 % Triton X-100 (0,5 ml) 
inPBS solution for 30 minutes. Cells were then treated with 300 nM (300 μl) DAPI in 
PBS for 5 min at dark according to the manufacturer protocol. The wells were washed 
thoroughly with PBS two times for 10 minutes in dark. Excess buffer was drained from 
coverslip and mounted. The fluorescent images were visualized by fluorescence 
microscope (Olympus ix71, USA). 
LysoTracker® Red DND-99 was used to stain lysosomes of A549 cells 
according to manufacturer protocol. Briefly, A549 cells (1ml, 5x10
5
 per well) were 
grown on coverslips inside 6 well plates with culture medium containing 10% 
FBS/RPMI and incubated in a humidified atmosphere (37ºC, 5% CO2)  for 24 hours. 
After incubation, Oregon Green labelled polymers (0,002 M) were added to wells (20 
μl) and incubated for 1 hour at 37 °C. The medium containing polymers was removed 
by washing with PBS three times. Before imaging, cells were incubated with 100 nM 
LysoTracker Red DND-99 (Invitrogen) in culture medium containing 10% FBS/RPMI 
for 1 hour in a humidified atmosphere (37ºC, 5% CO2). The wells were then washed 
three times with PBS and imaged using a fluorescence microscope. Excitation 
wavelengths were 358 nm, 496 nm, 577 nm and emission wavelengths were 461 nm, 
524 nm, 590 nm for DAPI, Oregon green, and LysoTracker Red DND-99 respectively.  
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CHAPTER 4  
RESULTS AND DISCUSSIONS 
4.1.  Physicochemical Characterization of Poly(ethylene glycol) Methyl 
Ether Acrylate p(PEG-A) and Linear PEG 
 
4.1.1. Chemical Structure and Molecular Weight Characterization 
 
Poly(polyethylene glycol) methyl ether acrylate p(PEG-A) with different 
molecular weights were synthesized by reversible addition fragmentation chain transfer 
(RAFT) polymerization according to the method reported in a previous publication 
(Heredia et al. 2008). The RAFT polymerization mechanism provides control over the 
molecular weight and molecular weight distribution (polydispersity index, PDI) of 
polymers (Rogošić, Mencer, and Gomzi 1996). The number average molecular weight 
(Mn) of the polymers synthesized by RAFT-controlled mechanism can theoretically be 
calculated according to 4.1. In this equation, the monomer conversion was determined 
by 
1
H-NMR analyses of the polymerization mixtures as described in previous 
publications and given in Appendix A (A.1 and A.2) (Boyer et al. 2009, Boyer, Bulmus, 
and Davis 2009). The actual Mn of the synthesized polymers was determined by both 
1
H-NMR and gel permeation chromatography (GPC) analyses of purified polymers 
Appendix A (A.3 and A.4). A measure of molecular weight distribution, polydispersity 
index (PDI), was also determined by GPC. The polymerization conditions and the 
properties of the resultant polymers are given in Table 4.1. The number-average 
molecular weight (Mn) was calculated from the 
1
H-NMR spectra of the polymers by 
taking the integral ratio of the characteristic peaks of the RAFT agent end-group (7.4 
and 7.2 ppm) to the characteristic peak of methylene of poly(PEG-A) (4.15 ppm) 
(Figure 4.1 and 4.2). These experimental Mn values obtained by NMR were in good 
agreement with the theoretical Mn values obtained from 4.1. Moreover, the PDI values 
that were determined by GPC showed narrow distribution of polymer chains. Thus, the 
low PDI values and the good agreement of the theoretical and experimental Mn values 
showed that the polymerization of PEG-A was controlled by the RAFT polymerization.  
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Theoretical molecular weight (Mn) = (conversion (%) × [M]0/[RAFT]0 × 
MW(monomer)) + MWRAFT.                                                                                     (4.1)                                                                         
                                                                                                             
Where [M]0 is the initial monomer concentration, [RAFT]0 is the initial 
concentration of the RAFT agent, MW(monomer) is the molecular weight of the monomer, 
MWRAFT is the molecular weight of the RAFT agent (Moad, Rizzardo, and Thang 2005, 
Lowe and McCormick 2007). 
 
Table 4.1. RAFT polymerization conditions and the properties of p(PEG-A) 10 and  
20K obtained  from RAFT polymerizations 
 
 
Polymer Code  [BSPA]0/[PEG-A]0/[AIBN]0
a 
     Time   Conversions
b
   Mn
c 
       Mn
d
         PDI
e
    Mn, theo
f 
 
                                                                                                   (hours)       (mol % )        (g/mol)      (g/mol)                         (g/mol)    
 
   p(PEG-A) 10K             1/30/0.2                       4          60          10 700    9 314    1,21      8912 
   p(PEG-A) 20K             1/60/0.2                       6          78          20 200   17 978   1,26   22 736 
a 
The molar ratio of monomer, RAFT agent and initiator.
 b 
The monomer conversion and 
c
 the number 
average molecular weight determined by 
1
H-NMR. 
d 
the number average molecular weight determined by 
GPC. 
e 
Polydispersity index determined by GPC. 
f
 The theoretical moleculer weight calculated by Mn, theo 
= (conversion (%) × [M]/[RAFT] × MW(monomer)) + MWRAFT. 
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Figure 4.1. 
1
H-NMR spectrum of purified p(PEG-A) 10K (Mn determined by 
1
H-NMR  
= 10 700 g/mol, Mn determined by GPC = 9 314 g/mol and PDI = 1,21)  
 
 
 
Figure 4.2. 
1
H-NMR spectrum of purified p(PEG-A) 20K (Mn determined by 
1
H-NMR 
= 20 200 g/mol, Mn determined by GPC = 17 978 g/mol and PDI = 1,26) 
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4.1.2. Dynamic Light Scattering Analysis 
 
The molecular size is an important parameter affecting the interactions of 
polymers with cells (Bures et al. 2001). Hydrodynamic size measurements of comb-type 
(p(PEG-A) 10K and 20K) and linear (PEG 10K and 20K) PEGs were performed in five 
different media using dynamic light scattering (DLS). Representative DLS data and 
results determined from DLS data are given in Appendix A ( Figure A.4) and Table 4.2, 
respectively. 
 
Table 4.2. Average hydrodynamic diameters (Dh) of polymers in different media (nm) 
(Measurements are the average±standard error of 9 different measurements) 
              
  H2O PBS 
PBS 
 
   RPMI 1640 
(containing 
10% FBS) 
(containing 
10% FBS) RPMI 1640 
PEG 10K 5.6±0.5 5.8±0.2 6.9±0.2 54.5±4.7 55.5±1 
PEG 20K 7.8±0.3 7.8±0.2 6.9±0.3 55.9±5.8 63.5±2 
p(PEG-A) 10K 4.5±0.3 5.6±1 6.4±0.4 44.4±1.8 51.5±4 
p(PEG-A) 20K 5.9±0.3 5.5±0.2 6.3±0.8 58±5.3 57.5±1.6 
 
 
The hydrodynamic diameter of comb-type PEG, p(PEG-A) polymers, was 
consistently found to be smaller than that of linear PEGs (except in RPMI 1640 medium 
only). This was attributted to the more compact architecture of the comb-type PEG with 
respect to linear PEG of the same molecular weight. The hydrophobic poly(acrylate) 
backbone and the hdyrophilic short PEG segments should take a more compact 
conformation in water when compared with the expanded, fully-solvated conformation 
of linear PEG backbone. In a previous study, hydrodynamic radius (Rh) of PEG 20K in 
water was measured as 3.45±2.5 (nm) which was quite close to the the size of linear 
PEG 20K obtained in this study (Linegar et al. 2010). The hydrodynamic diameters in 
water did not change significantly when PBS at pH 7.4 was used as a dispersant. 
Because of the non-charged structure of linear PEG and comb-type PEG, both polymers 
are not affected by the ions exist in PBS. In PBS containing 10% FBS, there was no 
significant change in hydrodynamic diameter of both types of PEG. PEG is known to 
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have non-fouling, protein-repelling character (Pacetti and Roorda 2010).  Thus the 
presence of serum proteins is not expected to cause any change in the conformation of 
neither linear PEG chains nor comb-type PEG chains.  
The hydrodynamic diameter (Dh) of linear PEG and comb-type PEG was also 
investigated in cell culture medium, RPMI 1640, or RPMI 1640 containing 10% FBS, 
which mimicks to some extent the physiological environment. The interactions of 
various components such as glucose, salts, amino acids present in RPMI 1640 or serum 
proteins present in RPMI 1640 containing serum with the polymers are important in 
mediating the uptake of macromolecules and particulates by cells (Wiogo et al. 2011). 
Such interactions are expected to cause conformation and hydrodynamic size changes in 
polymer chains, which should be detected easily via DLS measurements. Indeed, the Dh 
values of the polymers in RPMI 1640 containing 10% FBS and RPMI 1640 only 
sharply increased with respect to the Dh values in water and PBS (Table 4.2). There was 
no significant change in diameters obtained in RPMI 1640 containing 10% FBS and 
RPMI 1640 only, indicating that the increase in diameters was not caused by the 
interactions of serum proteins with the polymers. The components of RPMI 1640 
solution, i.e. glucose, amino acids may interact with both linear and comb-type PEGs 
possibly through the formation of hydrogen bonds between these components and 
oxygen of PEG. Importantly, there was no significant difference between the Dh values 
of comb-type PEGs (p(PEG-A)) and those of linear PEGs in both media, suggesting that 
the presence of hydrophobic -C-C- backbone of comb-type PEG does not lead to 
hydrophobic interactions with serum proteins or other components of RPMI 1640.  
 
4.1.3. AFM Analysis 
 
The AFM images of linear PEG having 10 000 g/mol (PEG 10K) and comb-type 
PEG having 10 700 g/mol (p(PEG-A) 10K) are presented in Figure 4.3. Both samples 
were prepared at the same concentration (0.05 mM) and imaged using tapping mode.  
Interestingly, while PEG 10K sample appeared to have linear structures, p(PEG-A) 10K 
appeared to form spherical structures. The width of the linear structures observed with 
PEG 10K sample was about 37.5 nm. The diameter of spherical structures observed 
with p(PEG-A) 10K was about 125 nm. These results suggest that both types of 
polymers undergo supramolecular associations, and the interchain interactions of linear 
and comb-type PEG differ significantly during the drying of samples before AFM 
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measurements. These interchain associations may be due to hydrophobic interactions 
between comb-type PEG chains and H bonding between linear PEG chains. Further 
investigations on the AFM measurements of these samples would be required in future: 
The concentration of polymer samples may be further reduced or the samples can be 
analyzed directly in solution (eliminating drying process) to better understand the 
morphology differences between these polymers in aqueous solutions. 
 
       
 
Figure 4.3. AFM images of (a) p(PEG-A) 10K (2 x 2 μm) (b) PEG10K (1 x 1 μm) 
 
4.2.  End-group Modifications of Comb-type and Linear PEG 
 End-group modification of polymers prepared by reversible addition–
fragmentation chain transfer (RAFT) polymerization has been widely carried out in 
literature by conversion of thiocarbonylthio end-group of the polymers into thiol groups 
which are able to conjugate easily with biomolecules, fluorescent molecules or other 
bioactive compounds (Boyer, Bulmus, and Davis 2009). The removal of the RAFT end-
group via such modifications is also useful to eliminate the possible toxicity of these 
groups (Pissuwan et al. 2010). A common synthetic route for the conversion of the 
RAFT end-group to thiol is the reduction or aminolysis of this group (Whittaker et al. 
2006, Li et al. 2008, Thomas et al. 2004). In this study, aminolysis of the comb-type 
PEGs synthesized by RAFT polymerization was carried out to convert these groups to 
thiols and subsequently attach (1) an ethylene glycol group to prepare ethylene glycol 
capped p(PEG-A) for cytotoxicity experiments or (2) a fluorescent dye to prepare 
fluorescent-labelled p(PEG-A) for cell uptake and intracellular distribution experiments. 
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The linear PEGs that were supplied from a manufacturer have already possesed 
a thiol end-group. They therefore were subjected directly to conjugation with (1) 
ethylene glycol group to prepare ethylene glycol capped PEG for cytotoxicity and cell 
cycle experiments or (2) a fluorescent dye to prepare fluorescent-labelled PEG for cell 
uptake and intracellular distribution experiments.  
 
4.2.1. Aminolysis of Comb-type PEG 
  
In order to create thiol end-group on the RAFT synthesized comb-type 
polymers, p(PEG-A) 10K and p(PEG-A) 20K were first aminolyzed. In the relevant 
literature, it is well-known that the trithiocarbonate RAFT end group can be easily 
reduced to thiol via a primary or secondary amine (Li et al. 2008, Thomas et al. 2004). 
A thiol group contains a carbon-bonded sulfhydryl (–C–SH or R–SH) group which 
allows easy and selective conjugation of biorelated molecules or flourescence dyes 
having unsaturated double bonds such as acrylate or maleimide to the end-group thiol 
modified polymers (Li et al. 2008). The aminolysis of p(PEG-A) 10K and 20K were 
performed in the presence of triethylamine (TEA) and hexylamine (HEA) at a [PEG-
A]0/[HEA]0/[TEA]0 mol ratio of 1/10/10 for 24 hours. The aminolysis reaction was 
monitored by UV-vis spectrophotometry. The polymers after aminolysis and 
purification were further analyzed by 
1
H-NMR spectroscopy to verify the removal of 
the RAFT end-group. 
As determined from the UV-vis spectroscopy of p(PEG-A) 20K before 
aminolysis, the RAFT end-group of the polymer has a maximum UV absorption at 
∼305 nm (Figure 4.5). After aminolysis this group leaves the polymer (Figure 3.2) and 
thus changes its structure leading to the shift of the maximum absorption wavelenght 
from 305 nm to 280 nm (Boyer et al. 2009). Figure 4.5 shows representative Uv-vis 
spectra of p(PEG-A) 20K before and after aminolysis, clearly revealing the cleavage of 
the RAFT end-group from the polymer chains. The control spectrum of amines only 
(TEA and HEA) shows that the presence of amines in the reaction medium does not 
interfere with the measurement of the RAFT end-group. Similar successful aminolysis 
reactions were reported in the literature. For example Boyer et al. reported the 
aminolysis of poly(hydroxypropylacrylamide) (PHPMA) via a similar method. The 
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authors also showed the disappearance of RAFT group signal at ∼305 nm after 
aminolysis (Boyer et al. 2009). 
1
H-NMR spectrum of aminolyzed p(PEG-A) 10K after purification is shown in 
Figure 4.4. In this spectrum, one can see that there are not any characteristic signals of 
the RAFT end-group at 2,70-2,80 ppm. This result evidences directly the success of 
aminolysis reaction which results in the formation of thiol-ended p(PEG-A) ready for 
subsequent modifications.  
 
 
 
Figure 4.4 
1
H-NMR spectrum of aminolyzed p(PEG-A) 10K after purification 
 
 
 
Figure 4.5. UV spectra of p(PEG-A) 20K in acetonitrile before and after aminolysis 
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4.2.2. Ethylene Glycol Ended-Polymers for Cytotoxicity Experiments 
 
The thiol end-groups of both linear and comb-type PEGs used in this study are 
potentially toxic as they are highly reactive chemical groups. Chang et al. showed that 
the thiol chain end was a significant source of toxicity and suggested that the toxicity 
can be reduced dramatically by masking the free thiol (Chang et al. 2009). Thus with 
the help of postpolymerization treatments, toxicity can be eliminated (Pissuwan et al. 
2010). 
Considering this, the thiol end-groups of commercial PEGs and aminolyzed 
p(PEG-A)s were masked by reacting with poly(ethylene glycol) methyl ether acrylate 
(PEG-A) (the repeating unit of p(PEG-A)). The polymers were then purified by dialysis 
to remove the excess of monomer which is a highly toxic compound. 
1
H-NMR 
spectroscopy of the purified polymers showed the absence of PEG-A monomer signals 
between 5,80 ppm and 6.4 ppm, thus indicating the complete removal of the excess 
monomer (Appendix B). 
 
4.2.3. Fluorescent Dye Labelled Polymers for Cell Uptake Experiments  
 
Fluorophores absorb light energy of a specific wavelength and re-emit light upon 
light excitation. This property can be used to stain biomolecules or polymers. A 
maleimide derivative of a fluorophore, Oregon Green® 488 Maleimide (OG) was used 
as an “ene” reagent that was conjugated to thiol-ended polymers through thiol-ene 
addition reaction. This created OG-labelled polymers with excitation/emission maxima 
of ~496/524 nm. Oregon Green®  488 maleimide has also been used by others as a 
thiol-reactive fluorophore to react with thiol groups on biomolecules to give fluorescent 
labelled biomolecules (Hermanson 1996). 
To enable the study of cell uptake and intracellular distribution profiles of comb-
type and linear PEGs, polymers were labelled with Oregon Green® 488 Maleimide. The 
fluorescence intensity of labelled polymers was analysed by fluorescence spectroscopy. 
The fluorophore number per polymer chain was also determined using Uv-vis 
spectroscopy at 491 nm (the extinction coefficient of OG at 491 nm = 81 000 M
-1
 cu
-1
). 
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Figure 4.6. Fluorescence spectra of Oregon Green® 488 labelled polymers. The  
concentration of all polymers was 0,0002 M. The spectra were with 
polymer solutions in deonize water. 
 
Fluorescence spectra of OG labelled polymers are shown in Figure 4.6. 
Considering that the equivalent concentrations for each polymer samples were used in 
the measurements, one can easily see that the fluorescence intensity of the linear 
polymers, PEG 10K and PEG 20K were higher than that of the comb-type PEGs, 
p(PEG-A) 10K and p(PEG-A) 20K. This might be attributed to the inefficient end-
group modification of comb-type PEGs as these polymers might have less end-groups 
available for dye attachment compared to linear PEGs. 
To quantify the labelling degree of the polymers (μg of OG/ mg of polymer), the 
comb-type and linear PEGs at the same molar concentrations were analysed by UV-vis 
Spectroscopy at 491 nm (Figure 4.7).  
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Figure 4.7. UV-vis spectra of Oregon Green® labelled polymers. The concentration of 
all polymers was 0,0002 M. The spectra were with polymer solutions in 
deonize water. 
 
Supporting the flourescence spectroscopy results, linear PEG 20K had the 
highest absorbance compared to the other polymers when detected with UV-vis 
spectroscopy. Based on the absorbance values of polymer solutions at 491 nm and the 
extinction coefficient of the dye, the OG content of polymers (μg of OG/ mg of 
polymer) was calculated according to the 4.2 considering all the dilutions made during 
measurements:  
 
         Abs labelled polymers = ε × concentration of dye x path lenght               (4.2) 
                                                                                           
Where Abs is the absorbance of the polymer solution at 491 nm, ε is the 
extinction coefficient of the dye at 491 nm (81 000 M
-1
 cu
-1
 according to the 
manufacturer). Using polymer molar concentrations used in the measurements, the 
degree of labeling  (μg of OG/ mg of polymer) was calculated. The degree of labelling 
for each polymer is given in Table 4.3.  
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Table 4.3. The OG content of linear and comb-type PEGs as determined from Uv-vis 
spectroscopy measurements 
 μg dye/ mg polymer 
 PEG 10K 
 
3.04 
 PEG 20K 
 
2.28 
 p(PEG-A) 10K 
 
0.94 
 p(PEG-A) 20K 1.44 
 
4.3. Cell Culture Results 
A549 cells (a human lung adenocarcinoma epithelial cell line) was used as 
adherent model carcinoma cell line to investigate cytotoxicity, cell uptake, cell cycle 
and intracellular distribution profiles of linear and comb-type PEGs. A549 cell line was 
used as a model cancer cell line as the lung cancer is one of the most common cancer 
types worlwide.  Importantly, it has been shown in the literature that the uptake of linear 
PEG by A549 cells is not favorable (Kunath et al. 2003).  
 
4.3.1. MTT Cell Viability Assay 
 
The effect of linear and comb-type PEG on the viability of in vitro cultured 
A549 cells were investigated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) cell viability assay (Berg, Hansen, and Nielsen 2009). In 
this assay, the ability of living cells to reduce a redox dye (tetrazole) into fluorescent 
dye (purple formazan) was measured. Viable cells signal fluorescence because their 
metabolic activity reduces the dye whereas the non-viable cells do not signal. The 
absorbance was measured at 570 nm using a microplate reader and depicted as a 
percentage relative to the untreated control cells.  
The comb-type PEG (p(PEG-A) 10K and p(PEG-A) 20K) and linear PEG (PEG 
10K and PEG 20K) at varying polymer concentrations (25 μM, 50 μM, 100 μM and 200 
μM)  were incubated with A549 for 24 or 72 hours. The cytotoxcitiy experiments were 
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performed in five-replicate. The percent viability of the cells treated with polymers was 
calculated according to the control (cells with no treatment) using Equation 3-1  (in 
Materials and Methods Section). The viability of A549 cells after treatment with the 
polymers for 24 h and 72 his shown Figure 4.8 and 4.9, respectively. Tables 4.4 and 4.5 
summarize the percentage cell viability together with statistical analysis results.   
  
 
 
Figure 4.8. Viability of A549 cells after incubation with comb-type PEGs (p(PEG-A) 
10K and p(PEG-A) 20K) and linear PEGs (PEG 10K and PEG 20K) for 24 
h. Control is the cells with no treatment.  
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Figure 4.9. Viability of A549 cells after incubation with comb-type PEGs (p(PEG-A) 
10K and p(PEG-A) 20K) and linear PEGs (PEG 10K and PEG 20K) for 72 
h. Control is the cells with no treatment.  
 
From Figure 4.8 PEG 10K caused no significant inhibition on A549 cell 
viability (93,79%) at the concentrations tested (p>0.05). PEG 20K caused the lowest 
cell viability (75,92%) only at 200 μM concentration. However, p(PEG-A) 10K and 
p(PEG-A) 20K caused statistically significant reduction on the cell viability (p<0.05). 
At 200 μM concentration, p(PEG-A) 10K (63,08%) and p(PEG-A) 20K (59,64%) 
showed maximum toxic effect (p<0.05). However, even these maximum values were 
above the 50% cell viability, showing that p(PEG-A) do not cause a major toxicity on 
A549 cells after 24 h incubation.  
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Table 4.4. Percent Viability of A549 cells after incubation with comb-type PEGs 
(p(PEG-A) 10K and p(PEG-A) 20K) and linear PEGs (PEG 10K and PEG 
20K) for 24 h. 
 
Polymers 
Concentrations     p(PEG-A) 10K p(PEG-A) 20K PEG 10K PEG 20K 
Control 100±19.27a,A 100±19.3a,A 100±6.60a,A 100±6.60a,A 
25 μM 73.29±3.92bc,AB 71.25±14.3b,AB 105.92±11.24a,A 80.94±6.31bc,B 
50 μM 72.83±12.22bc,A 71.89±11.3b,A 94.08±13.42a,A 88.90±9.14ab,A 
100 μM 84.75±7.87ab,A 76.29±7.0b,A 97.72±20.51a,A 86.82±4.56bc,A 
200 μM 63.08±8.80c,AB 59.64±4.1b,A 93.79±6.66a,B 75.92±2.93c,A 
a-c 
Values within each concentration followed by the same letter are not significantly different (p > 0.05). 
A-B 
Values within each polymer followed by the same letter are not significantly different (p > 0.05). 
Data are means values ± one standard deviation (n=5).  
 
In literature, Pissuwan et al. (Pissuwan et al. 2010) investigated the effect of 
p(PEG-A) (Mn = 11 100 g/mol) on the viability of three different cell lines (CHO-K1, 
NIH3T3, and Raw264.7) for 24 h and 72 h upto 1 mM or ∼10 mg/mL polymer 
concentratios. After incubating the cells with the polymers the cell viability was 
evaulated by a CellTiter-Blue assay. p(PEG-A) did not cause any significant cytotoxic 
effect on any of the cell types over 24 h. Also it was noted that p(PEG-A) was nontoxic 
over 72 h to CHO-K1 and NIH3T3 cells while it showed dose-dependent toxicity on 
RAW264.7 cells. These results indicate that the effect of p(PEG-A) on the viability of 
cells depends on the cell type.   
The viability of A549 cells after treatment with the polymers for 72 h is shown 
in Figure 4.9 and Table 4.5. From the figure Figure 4.10, PEG 10K and PEG 20K 
caused slight inhibition on the viability of A549 cells (77,9%) and (62,9%), respectively 
at 200 μM (p<0.05). Compared to 24 h results, PEG 10K and PEG 20K showed more 
cytotoxic effect on A549 cells in 72 h. However, the effect of p(PEG-A) 10K and 
p(PEG-A) 20K on the cell viability was less than the effect of the same polymers in 24 
h. It is possible that the cell growth in 72 h minimizes the cytotoxic effect of p(PEG-A).  
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Table 4.5. Percent Viability of A549 cells after incubation with comb-type PEGs 
(p(PEG-A) 10K and p(PEG-A) 20K) and linear PEGs (PEG 10K and PEG 
20K) for 72 h. 
 
Polymers 
Concentrations     p(PEG-A) 10K p(PEG-A) 20K PEG 10K PEG 20K 
Control 100±22.69a,A 100±22.69a,A 100±29.2a,A 100±29.2a,A 
25 μM 99,07±6.66ab,A 89.95±8.8ab,A 106.7±26.4a,A 64.6±6.3b,B 
50 μM 78.08±4.03bc,A 82.23±6.1abc,A 79.7±15.5a,A 80.4±5.4ab,A 
100 μM 80.17±1.67abc,A 73.67±3.3bc,A 87.3±10.0a,A 74.4±8.7ab,A 
200 μM 76.29±8.79c,A 63.86±4.8c,B 77.7±8.4a,AB 62.9±3.5b,B 
a-c 
Values within each concentration followed by the same letter are not significantly different (p > 0.05). 
A-B 
Values within each polymer followed by the same letter are not significantly different (p > 0.05). 
Data are means values ± standard deviation (n=5). 
 
4.3.2. Cell Uptake  
 
Uptake of OG-labelled linear and comb-type PEGs by A549 cells was 
investigated using flow cytometry that enabled quantitative analysis of fluorescence–
associated cells at an extremely rapid rate. Firstly, four different polymers at 12.5 µM 
concentration was incubated with cells at 37ºC for 1, 3 and 6 hours. The mean green 
fluorescence values (total fluorescence collected in the channel normalized accroding to 
the total cell count in the A549-cells region) were used to indicate the cell uptake of 
polymers. It should be noted that as the degree of labelling differed for each polymer 
type (Table 4.3), the mean green fluorescence values obtained with each type of 
polymer were normalized according to the labelling degree of p(PEG-A) 10K, the 
polymer with the lowest labelling degree. Additionally, the uptake of polymers with no 
label was also investigated by flow cytometry as a control experiment (Appendix C). 
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Figure 4.10. Uptake of comb-type PEGs (p(PEG-A) 10K and p(PEG-A) 20K) and linear  
PEGs (PEG 10K and PEG 20K) by A549 cells in 1, 3 and 6 hours at 37 
°C. The polymer concentration was 12.5 µM. Experiments were performed 
in triplicate. 
 
In addition, Figure 4.10 shows the mean fluorescence intensity (per cell) as a 
function of incubation time and polymer type.  The maximum cell uptake was observed 
with p(PEG-A) 10K. The other polymers showed similar uptake profiles for 1 hour 
incubation. For 3 and 6 hours, the uptake of PEG 10K was slightly higher than p(PEG-
A) 20K and PEG 20K, however it was still far less than p(PEG-A) 10K. p(PEG-A) 10K 
is has the smallest hydrodynamic volume (Table 4.2). It might be easier for cells to take 
up the most compact polymer structure. For all polymer samples, the mean cell uptake 
at 37 °C was not a function of time. 
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Table 4.6. Mean Fluorescence Intensity of comb-type PEGs (p(PEG-A) 10K and 
p(PEG-A) 20K) and linear PEGs (PEG 10K and PEG 20K) by A549 cells in 
1, 3 and 6 hours at 37 °C. The polymer concentration was 12.5 µM. 
 
Polymers 
Mean 
Fluorescence 
Intensity(hour)    
p(PEG-A) 10K p(PEG-A) 20K PEG 10K PEG 20K 
1. 94.67±2.31a,A 45.15±7.24a,B 51.82±8.34a,B 48.65±1.64a,B 
3. 110.00±9.54a,A 30.14±1.36b,C 48.77±5.24a,B 29.82±2.09b,C 
6. 108.67±6.66a,A 39.17±3.68ab,C 56.99±6.43a,B 32.43±2.28b,C 
a-b 
Values within each mean fluorescence intensity followed by the same letter are not significantly 
different (p > 0.05). 
A-C 
Values within each polymer followed by the same letter are not significantly different (p > 0.05). 
Data are means values ± one standard deviation (n=3). 
 
The time-dependent cell uptake of polymers was also analyzed at 4 
°
C by flow 
cytometry. As seen in Figure 4.11 when compared to the uptake at 37 
°
C, cell-associated 
mean fluorescence of all polymers significantly decreased at 4 
°
C. Endocytosis, 
phagocytosis and pinocytosis are known as general cell entry mechanisms for various 
extracellular materials. These mechanismsare energy-dependent, thus they are hindered 
at low temperatures (such as 4 
◦
C) (Marsh and McMahon 1999, Silverstein, Steinman, 
and Cohn 1977). 
Interestingly, the uptake of both p(PEG-A) and PEG having 20K molecular 
weight by A549 cells at 4 
°
C increased with time. This effect was more profound with 
linear PEG 20K. This observation suggests that the higher molecular weight polymers 
enter A549 cells via a passive mechanism. This mechanism needs to be investigated in 
future studies.  
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Figure 4.11. Uptake of comb-type PEGs (p(PEG-A) 10K and p(PEG-A) 20K) and linear 
PEGs (PEG 10K and PEG 20K) by A549 cells in 1, 3 and 6 hours at 4 °C. 
The polymer concentration was 12.5 µM. Experiments were performed in 
triplicate.  
 
 
Table 4.7. Mean Fluorescence Intensity of comb-type PEGs (p(PEG-A) 10K and 
p(PEG-A) 20K) and linear PEGs (PEG 10K and PEG 20K) by A549 cells in 
1, 3 and 6 hours at 4 °C. The polymer concentration was 12.5 µM. 
 
Polymers 
Mean 
Fluorescence 
Intensity(hour)    
p(PEG-A) 10K p(PEG-A) 20K   PEG 10K   PEG 20K 
1. 47.67±2.08a,A 8.48±0,3a,C 15.51±0.52a,B 14.10±3.87a,BC 
3. 32.66±0.57c,A 22.52±0.86b,B 10.24±0.17c,D 19.17±1.03a,C 
6. 40.30±2.08b,A 37.97±4.24c,A 13.58±6.35b,B 36.6±1.76b,A 
a-c 
Values within each mean fluorescence intensity followed by the same letter are not significantly 
different (p > 0.05). 
A-D 
Values within each polymer followed by the same letter are not significantly different (p > 0.05). 
Data are means values ± one standard deviation (n=3). 
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Figure 4.12. Uptake of comb-type PEGs (p(PEG-A) 10K and p(PEG-A) 20K) and linear 
PEGs (PEG 10K and PEG 20K) at varying concentrations (12,5, 25 and 50 
µM) by A549 cells in 1 hours at 37 °C. Experiments were performed in 
triplicate.  
 
To determine whether the active cell uptake is dependent on the dose of 
polymers, varying concentrations of polymers were incubated with A549 cells at 37 ºC 
for 1 hour (Figure 4.12). The data indicated that the uptake of all polymers by A549 
cells increased with increasing polymer concentrations in the studied range. p(PEG-A) 
10K appeared to have the highest uptake at all concentrations when compared to other 
polymers tested.  
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Table 4.8. Mean Fluorescence Intensity of comb-type PEGs (p(PEG-A) 10K and 
p(PEG-A) 20K) and linear PEGs (PEG 10K and PEG 20K) by A549 cells in 
1 hour at 37 °C. The polymer concentration was 12.5 µM, 25 µM and 50 
µM. 
 
Polymers 
Mean 
Fluorescence 
Intensity 
(concentration)    p(PEG-A) 10K p(PEG-A) 20K    PEG 10K    PEG 20K 
12.5 µM 94.67±2.31a,A 45.15±7.24a,B 51.82±8.34a,B 48.65±1.64a,B 
25 µM 113.67±2.08b,A 55.95±12.40ab,B 50.91±5.11a,B 45.90±3.29a,B 
50 µM 189.0±12.73c,A 85.51±9.23b,B 96.59±17.86b,B 99.57±8.75b,B 
   a-c 
Values within each mean fluorescence intensity followed by the same letter are not significantly   
   different (p >  0.05). 
   A-B 
Values within each polymer followed by the same letter are not significantly different (p > 0.05). 
  Data are means values ± one standard deviation (n=3). 
 
 
4.3.3. Cell Cycle 
 
Since p(PEG-A) 10K and p(PEG-A) 20K at 200 μM concentration caused 
statistically significant reduction on the cell viability (63,08% and 59,64%, respectively) 
in 24 hours, whereas there was no significant cytotoxic effect of linear PEGs. 
Considering these results, the effect of both types of polymers on the cell cycle was 
investigated by incubating four different polymers at 200 μM concentration with A549 
cells at 37 ºC for 24 hours.   
Cell division is divided into two stages: mitosis (M) which is the process of 
nuclear division and interphase which is the interlude between two M phases. Interphase 
consists of G1, S and G2 phases. G1, S, G2 and M phases are the traditional 
subdivisions of the standard cell cycle. Replication of DNA occurs in S phase. S phase 
is preceded by G1 phase during which the cell is preparing for DNA synthesis and 
followed by G2 phase during which the cell prepares for mitosis (Vermeulen, Van 
Bockstaele, and Berneman 2003). 
To investigate the effects of polymers on cell cycle, DNA-content was measured 
by flow cytometry after propidium iodine (PI) staining. Additionally, DNA distribution 
was analyzed by ModFit software. The flow cytometry data are given in Appendix D.     
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Figure 4.13 and Figure 4.14 show the DNA distribution of A549 cells 
determined from the flow cytometry data. The results indicated that none of the 
polymers caused an arrest on cell cycle over 24 or 72 hour compared to control 
experiment. At 72 hour, the result indicates that the rate of  DNA synthesis was retarded 
and thus slowed the progress of cells through S phase. However,  the percentage of 
G2/M cells did not alter when compared to control experiments. G1 and S phases did 
not display an arrest and were nearly close to G1 and S phases of untreated control 
A549 cells. Also, DNA distribution of A549 cells after 24 hour treatment at 4 and 37 °C 
was shown in Appendix D (Figure D.3). Cells at 4 °C do not lose their viability as 
indicated by cell cycle experiment results. 
 
    
 
Figure 4.13. DNA distribution of A549 cells after 24 hour treatment with polymers at 
200 μM. Experiments were performed in triplicate. 
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Figure 4.14. DNA distribution of A549 cells after 72 hour treatment with polymers at 
200 μM. Experiments were performed in duplicate. 
 
4.3.4. Intracellular Distribution  
 
To investigate intracellular localization of polymers, green-fluorescent labelled 
polymers were incubated with cells followed by staining nucleus with blue fluorescent 
dye or lysosomes with red fluorescent dye, and then imaging by a fluorescence 
microscope. The fluorescence images are shown in Figures 4.15 – 4.22.  In all cases, 
polymers were taken up by A549 cells, as green fluorescence was apparent inside the 
cells. None of the polymers entered the nucleus of cells, as expected. It was seen in 
emerged images that polymers localized mostly in lysosomes, and partially within 
cytoplasm.  These results together with flow cytometry analyses suggest that both 
comb-type and linear PEGs are taken up by cells via energy-dependent active 
mechanism, such as endocytosis as a common mechanism for soluble macromolecules. 
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Figure 4.15. Fluorescence microscopic images of A549 cells after 1 hour incubation 
with (a) Oregon green labeled with p(PEG-A) 10K (green), (b) colabeled 
with DAPI (blue); (c) merged image of a and b: ×100 (scale bar: 30 μm) 
 
 
Figure 4.16. Fluorescence microscopic images of A549 cells after 1 hour incubation 
with (a) Oregon green labeled with PEG 10K (green), (b) colabeled with 
DAPI (blue); (c) merged image of a and b: ×100 (scale bar: 30 μm) 
 
 
Figure 4.17. Fluorescence microscopic images of A549 cells after 1 hour incubation 
with (a) Oregon green labeled with p(PEG-A) 20K (green), (b) colabeled 
with DAPI (blue); (c) merged image of a and b: ×100 (scale bar: 30 μm) 
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Figure 4.18. Fluorescence microscopic images of A549 cells after 1 hour incubation 
with (a) Oregon green labeled with PEG 20K (green), (b) colabeled with 
DAPI (blue); (c) merged image of a and b: ×100 (scale bar: 30 μm) 
 
 
Figure 4.19. Fluorescence microscopic images of A549 cells after 1 hour incubation 
with (a) Oregon green labeled with p(PEG-A) 10K (green), (b) colabeled 
with LysoTracker® Red DND-99 (red); (c) merged image of a and b: ×40 
(scale bar: 30 μm) 
 
 
Figure 4.20. Fluorescence microscopic images of A549 cells after 1 hour incubation 
with (a) Oregon green labeled with PEG 10K (green), (b) colabeled 
LysoTracker® Red DND-99 (red); (c) merged image of a and b: ×40 
(scale bar: 30 μm) 
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Figure 4.21. Fluorescence microscopic images of A549 cells after 1 hour incubation 
with (a) Oregon green labeled with p(PEG-A) 20K (green) , (b) colabelled 
with LysoTracker® Red DND-99 (red); (c) Merged image of a and b: ×40 
(scale bar: 30 μm) 
 
 
Figure 4.22. Fluorescence microscopic images of A549 cells after 1 hour incubation 
with (a) Oregon green labeled with PEG 20K (green), (b) colabelled 
LysoTracker® Red DND-99 (red); (c) Merged image of a and b: ×40 
(scale bar: 30 μm) 
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CHAPTER 5 
CONCLUSION 
To the best of the author’s knowledge, there has been no reports in literature on 
the comparison of the physicochemical characteristics and in vitro cell interactions of 
linear and comb-type PEGs. Therefore, the first specific objective of this study was to 
investigate the morphology and hydrodynamic size of comb-type and linear PEGs of 
equivalent molecular weights. The second specific objective was to provide a 
preliminary work on in vitro cytotoxicity, cell uptake, cell cycle and intracellular 
distribution profiles of comb-type and linear PEGs.  
In this context, linear PEGs having two different molecular weights (Mn=10 000 
g/mol and 20 000 g/mol (PEG 10K and PEG 20K)) were purchased from a 
manufacturer. These molecular weights were selected as they are in the range of 
molecular weights that are used commonly in PEGylation applications. The comb-type 
PEGs, p(PEG-A), with two different molecular weights (Mn= 10 700 g/mol and Mn= 20 
200 g/mol p(PEG-A) 10K and p(PEG-A) 20K) were synthesized by a controlled 
polymerization technique, RAFT polymerization, according to a method reported in 
previous publications. Polymers were characterized by using Nuclear Magnetic 
Resonance (NMR), Gel Permeation Chromatography (GPC), Dynamic Light Scattering 
(DLS) and Atomic Force Microscopy (AFM) methods. A combination of the results 
obtained from NMR spectroscopy and GPC measurements showed clearly the 
successful synthesis of the controlled molecular weight and narrow polydisperse comb-
type PEGs. DLS was used to measure the hydrodynamic diameter (Dh) of polymers in 5 
different media: phosphate buffer saline (PBS) at pH 7.4, PBS containing 10% fetal 
bovine serum (FBS), cell culture medium  RPMI-1640, and RPMI-1640 containing 10% 
FBS. Compared to linear PEG, the comb-type polymers had a smaller Dh in water and 
PBS. All polymers tested in aqueous solutions had a Dh value less than 7.8 nm. The Dh 
values of all polymers showed a significant increase in cell culture media, RPMI 1640 
and RPMI 1640 containing 10% FBS, indicating the existence of interactions between 
medium components and polymers possibly through hydrogen bonding. While p(PEG-
A) 10K in RPMI 1640  had the smallest size of 44.4 nm, p(PEG-A) 20K in the same 
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medium had the largest size of 58 nm. The linear PEGs in RPMI 1640 had Dh values 
between 54.5 nm and 55.9 nm. Similar Dh values were obtained for polymers in RPMI 
1640 containing 10% FBS. The morphology of both PEG 10K and p(PEG-A) 10K was 
investigated by AFM. The AFM image of PEG 10K displayed the formation of linear 
structures whereas supramolecular spherical structures were observed clearly with 
p(PEG-A) 10K, indicating significant differences between interchain interactions of 
linear and comb-type PEGs.  
The interactions of comb-type and linear poly(ethylene glycol) with equivalent 
molecular weights with in vitro cultured cells were investigated using A549 human lung 
adenocarcinoma epithelial cells as a model cancer cell line, as lung cancer is one of the 
most common cancers worlwide and the uptake of linear PEG by A549 cells has been 
shown in literature to be inefficient. 
The cytotoxic effect of polymers on the viability of A549 cells was investigated 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) Cell Viability 
assay. Comb-type PEGs were statistically more cytotoxic than linear PEGs after 24 
hours treatment. Nevertheless, the minimum cell viability observed after 24 with the 
comb-type polymers at the highest concentration tested (200 µM) was above 59%. The 
cell viability after treatment with p(PEG-A) (10K and 20K) for 72 hours increased when 
compared with the cell viability after 24 hours, and reached the similar values with 
those of linear PEGs. This was attributed to the the growth of cells in 72 hours 
minimizing the cytotoxic effects of polymers.   
The uptake of comb-type and linear PEGs by A549 cells was investigated as a 
function of incubation time (1-6 hours), incubation temperature (37 and 4 ºC) and 
polymer concentration (12.5 – 50 µM). Overall the cell uptake results showed that all 
polymers are taken up efficiently by A549 cells at 37 ºC in 1 hour, however when 
compared to other polymers, p(PEG-A) 10K is taken up at significantly higher amounts 
by the cells at 37 ºC.  The cell uptake of polymers at 37 °C increased with increasing 
polymer concentrations in the studied range. When compared to 37 °C, the cell uptake 
of all polymers significantly decreased at 4 °C. This indicated that the main cell entry 
mechanism of the polymers is via an energy-dependent mechanism such as 
phagocytosis, pinocytosis and endocytosis. The intracellular distribution of polymers by 
A549 cells was visualized by a fluorescence microscope. Both type of polymers were 
found in the cytoplasm and lysosomes of the cells. None of the polymers entered the 
nucleus of cells. The microscopy data support the results observed by flow cytometry. 
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 Furthermore the effect of polymers on the cell cycle was investigated by flow 
cytometry for 24 and 72 hour. Both polymers p(PEG-A) 10K and 20K , and PEG 10K 
and 20K did not affect at all the cell cycle phases under the conditions tested compared 
to control experiments.  
Overall the study presented in this thesis provided for the first time a preliminary 
comparative investigation on the physicochemical properties of linear and comb-type 
PEGs and their interactions with an in vitro cultured cancer cell line.  
Future investigations on the topic may include the following suggestions:  
1. The morphology of the cells can be investigated by AFM under liquid, which will 
show the hydrodynamic conformation or organization of the polymers. This would 
make the AFM data be more comparable with DLS data although liquid AFM still 
requires a substrate surface. 
2. The cytotoxicity, cell uptake, cell cycle and intracellular distribution experiments can 
be done using various healthy cells and other cancer cells to derive general conclusions. 
3. The cytotoxicity, cell uptake and cell cycle experiments can be performed at 
significantly higher concentrations of polymers to determine the critical concentrations 
of polymers causing significant effects on cells.  
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APPENDIX A 
 
CHARACTERIZATION 
 
 
Figure A.1. 
1
H-NMR spectrum of non-purified p(PEG-A) 10 K                            
Conversion determined by 
1
H-NMR spectrum of non-purified PEG-A 
that synthesized by RAFT polymerization at 65 °C, at a 
[BSPA]0/[PEG-A]0/[AIBN]0 = 1/30/0.2  
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Figure A.2. 
1
H-NMR spectrum of non-purified p(PEG-A) 20K.                               
Conversion determined by 
1
H-NMR spectrum of non-purified PEG-
A that synthesized by RAFT polymerization at 65 °C, at a 
[BSPA]0/[PEG-A]0/[AIBN]0 = 1/60/0.2 
 
 
                     Yield (mol %) = (( Ie-Ie’)/ (Ie+Ie’)) x 100 mol %                  (A.1) 
                                                                                             
In this equation; Ie refers to integration values of reacted PEG-A and Ie’ refers 
to un-reacted PEG-A. 
 
  
 
Figure A.3. GPC chromotograms of p(PEG-A) (10 and 20K) synthesized via RAFT             
                 polymerization. (a) elugram of p(PEG-A) (Mn = 10 700 g/mol,  
                 PDI =1.21 ) b) elugram of p(PEG-A) (Mn = 20 200 g/mol PDI = 1.26) 
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Figure A.4. Hydrodynamic diameter (Dh) of polymers obtained by DLS (measurement 
range 0.3nm – 10.0 microns). The Dh of linear PEGs (PEG 10K and 20K) 
and comb-type PEGs (p(PEG-A) 10K and p(PEG-A) 20K)  in (a) water (b) 
PBS (c) PBS containing 10% FBS (d) RPMI 1640(e) RPMI 1640 containing 
10% FBS  
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APPENDIX B 
 
ETHYLENE GLYCOL ENDED-POLYMERS 
 
 
 
Figure B.1. 
1
H-NMR spectrum of p(PEG-A) 10K after binding of PEG-A and  
purification by dialysis.  
 
 
 
Figure B.2. 
1
H-NMR spectrum of p(PEG-A) 20K after binding of PEG-A and 
purification by dialysis 
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Figure B.3. 
1
H-NMR spectrum of PEG 10K after binding of PEG-A and purification by 
dialysis. 
 
 
 
 
 
Figure B.4. 
1
H-NMR spectrum of p(PEG-A) 20K after binding of PEG-A and   
purification by dialysis.  
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APPENDIX C 
 
CELL UPTAKE OF LINEAR PEG (10K AND 20K) AND COMB-
TYPE PEG p(PEG-A) (10K AND 20K) 
 
 
                                                        
Figure C.1. Uptake of polymers (12,5 μM) by A549 cells in 1 hour at 37 ◦C a) Control 
b) Linear PEG 10K c) Comb-type PEG, p(PEG-A) 10K d) no labelled linear 
PEG 10K  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) b)
c) d)
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Figure C.2. Uptake of polymers (12,5 μM) by A549 cells in 3 hour at 37 ◦C a) Control 
b) Linear PEG 10K c) Comb-type PEG, p(PEG-A) 10K d) no labelled linear 
PEG 10K 
 
 
 
Figure C.3. Uptake of polymers (12,5 μM) by A549 cells in 6 hour at 37 ◦C a) Control 
b) Linear PEG 10K c) Comb-type PEG, p(PEG-A) 10K d) no labelled linear 
PEG 10K 
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Figure C.4. Uptake of polymers (12,5 μM) by A549 cells in 1 hour at 37 ◦C a) Control 
b) Linear PEG 20K c) Comb-type PEG, p(PEG-A) 20K d) no labelled linear 
PEG 20K 
 
 
 
Figure C.5. Uptake of polymers (12,5 μM) by A549 cells in 3 hour at 37 ◦C a) Control 
b) Linear PEG 20K c) Comb-type PEG, p(PEG-A) 20K d) no labelled 
linear PEG 20K 
 
 
a) b)
c) d)
a) b)
c) d)
 
69 
 
 
 
Figure C.6. Uptake of polymers (12,5 μM) by A549 cells in 6 hour at 37 ◦C a) Control 
b) Linear PEG 20K c) Comb-type PEG, p(PEG-A) 20K d) no labelled linear 
PEG 20K 
 
 
 
 
Figure C.7. Uptake of polymers (12,5 μM) by A549 cells in 1 hour at 4◦C a) Control    
b) Linear PEG 10K c) Comb-type PEG, p(PEG-A) 10K  
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Figure C.8. Uptake of polymers (12,5 μM) by A549 cells in 3 hour at 4 ◦C a) Control   
b) Linear PEG 10K c) Comb-type PEG, p(PEG-A) 10K  
 
 
 
 
Figure C.9. Uptake of polymers (12,5 μM) by A549 cells in 6 hour at 4 ◦C a)            
Control b) Linear PEG 10K c) Comb-type PEG, p(PEG-A) 10K 
a) b)
c)
a) b)
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Figure C.10. Uptake of polymers (12,5 μM) by A549 cells in 1 hour at 4 ◦C a)           
Control b)  Linear PEG 20K c) Comb-type PEG, p(PEG-A) 20K 
 
 
 
Figure C.11. Uptake of polymers (12,5 μM) by A549 cells in 3 hour at 4 ◦C a)           
Control b)  Linear PEG 20K c) Comb-type PEG, p(PEG-A) 20K 
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Figure C.12. Uptake of polymers (12,5 μM) by A549 cells in 6 hour at 4 ◦C a)           
Control b) Linear PEG 20K c) Comb-type PEG, p(PEG-A) 20K 
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Figure C.13. Uptake of polymers (25 μM) by A549 cells in 1 hour at 37 ◦C a)           
Control b)  Linear PEG 10K c) Comb-type PEG, p(PEG-A) 10K d) 
Linear PEG 20K, e) Comb-type PEG, p(PEG-A) 20K   
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Figure C.14. Uptake of polymers (50 μM) by A549 cells in 1 hour at 37 ◦C a)           
Control b)  Linear PEG 10K c) Comb-type PEG, p(PEG-A) 10K d) 
Linear PEG 20K, e) Comb-type PEG, p(PEG-A) 20K   
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APPENDIX D 
 
FACS ANALYSIS OF CELL CYCLE 
 
 
  
Figure D.1. FACS analysis of cell cycle induced by polymers for 24 hour. a) Control 
experiment b) PEG 10K, c) PEG 20K, d) p(PEG-A) 10K, e) p(PEG-A) 20K  
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Figure D.2. FACS analysis of cell cycle induced by polymers for 72 hour. a) Control 
experiment b) PEG 10K, c) PEG 20K, d) p(PEG-A) 10K, e) p(PEG-A) 20K  
 
    
Figure D.3. DNA distribution of A549 cells after 24 hour treatment at 4 and 37 °C 
Experiments were performed in triplicate. 
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